Full history for every metric is available with a Kvantra account
Cidara Therapeutics, Inc. (CDTX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 21 | 12 | 50 | 64 | 23 | 1 |
| Operating profit | $m | -176 | |||||
| Net profit | $m | -41 | -72 | -42 | -34 | -23 | -170 |
| EPS reported | $ | -26.75 | |||||
| Operating cashflow per share | $ | -27.80 | |||||
| Capex per share | $ | 0.02 | |||||
| FCF per share | $ | -27.82 | |||||
| Free cash flow | $m | -177 | |||||
| Net debt | $m | -190 | |||||
| Book value equity | $m | 163 | |||||
| Book value per share | $ | 25.72 | |||||
| Number of shares | m | 6.35 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 1.05 | |||||
| P/S LTM | x | 133.87 | |||||
| P/FCF LTM | x | -0.97 | |||||
| EV/EBITDA LTM | x | 0.09 | |||||
| EV/Sales LTM | x | -12.21 | |||||
| Earnings Yield LTM | % | -99.50% | |||||
| FCF Yield | % | -103.51% | |||||
| Quality | |||||||
| ROE | % | -103.99% | |||||
| ROIC | % | -105.52% | |||||
| Operating margin | % | -13811.9% | |||||
| Gross margin | % | 100.00% | |||||
| FCF/Sales | % | -13855.8% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -94.52% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -49.40 | |||||
| Net Debt/EBITDA | x | 1.10 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -111.22% | |||||
| Net debt/Equity | x | -1.16 | |||||
| Gross debt/equity | x | 0.02 | |||||
Company overview
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free